|
|
News Breaks | | | | January 30, 2013 | | 08:50 EDT |  | RPRX | Repros Therapeutics weakness creates buying opportunity, says Roth Capital
After Repros' stock sold off yesterday, Roth Capital spoke with the company's management and is more confident that the outlook for the company's Androxal drug remains positive. The firm maintains a $19 price target and Buy rating on the stock. | |
|
News For RPRX From The Last 14 Days Check below for free stories on RPRX the last two weeks. |
|
|
| June 19, 2013 | | 11:33 EDT |  | RPRX | Stocks with call strike movement; BBRY RPRX
 Subscribe for More Information | | | June 17, 2013 | | 16:02 EDT |  | RPRX | Repros Therapeutics commences offering of 3M shares of common stock
Subscribe for More Information | | | 14:21 EDT |  | RPRX | Repros Therapeutics amends PHS patent license agreement
In a regulatory filing, Repros Therapeutics disclosed that on June 14, Repros entered into the Ninth Amendment to the PHS Patent License Agreement dated April 16, 1999, by and between the National Institutes of Health, the Centers for Disease Control or the Food and Drug Administration, collectively, the Public Health Service or PHS, agencies of the United States Public Health Service within the Department of Health and Human Services and the company.The Ninth Amendment substitutes and amends the development benchmarks that the company is required to meet under the Agreement. The company is also filing herewith the Eighth Amendment to the Agreement dated April 20, 2010, which added additional molecules licensed to the Company from PHS under the Agreement. | | | June 12, 2013 | | 11:32 EDT | | RPRX | Options with decreasing implied volatility: TIVO LAMR FRAN RPRX NAV
| |
|
|
|
|
|
|
